Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
The European Union will respond in kind if the U.S. imposes tariffs on France over digital tax plan, EU chief Donald Tusk told G-7.Technologyread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
The final week of August could be highly volatile as markets fret over the economy and the latest developments in trade wars.Market Insiderread more
Federal Reserve Vice Chair Richard Clarida said Friday that the global economy has deteriorated in the past month.Marketsread more
The latest escalation in the trade war ups the odds the economy will fall into recession and that the Fed will aggressively cut rates.Market Insiderread more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
"We don't need China and, frankly, would be far better off without them," Trump tweeted.Politicsread more
Recent trade friction between the two Asian powerhouses has morphed into a dispute with political implications that go far beyond the region.Asia Politicsread more
"My only question is, who is our bigger enemy, Jay Powell or Chairman Xi?" Trump wrote amid a series of tweets that rattled markets Friday.Politicsread more
"I would love this to be clarified. We come to a deal on trade, boy, this market is up 10 to 15%, but without it's going to be worrisome," Jeremy Siegel says.Marketsread more
When your drug sets a record for the fastest launch in history, everyone wants a piece of it.
That's the case with Gilead Sciences' hepatitis C drug Sovaldi, which drew a record $2.27 billion in revenue in its first full quarter on the market. The Foster City, California-based company is competing with Merck, AbbVie, Bristol-Myers, Johnson & Johnson and others to treat an estimated 150 million people worldwide with drugs that are easier to take and have higher cure rates for hepatitis C.
Merck's $3.85 billion acquisition of Idenix, announced Monday, gives it additional experimental medicines to add to its arsenal. Idenix is developing a medicine in a class called "nucs," or nucleotide polymerase inhibitors, a valuable part of new treatment regimens.
In announcing the deal, Merck also reinforced expectations for the size and durability of the hepatitis C market.
"They seem to endorse a 2018 worldwide hepatitis C sales estimate of more than $20 billion," ISI Group analyst Mark Schoenebaum wrote in a research note.
Gilead is still considered the leader, but its stock is down 3.9 percent. So what's up? (To get the latest quote for Gilead, click here.)
Analysts say there's more to Merck's interest in Idenix than its drug portfolio: intellectual property. Both Merck and Idenix have separately claimed they own the IP behind Gilead's Sovaldi. Individually, the claims may not have been as strong. Together, they hold more weight, said Robert W. Baird analyst Brian Skorney.
"There's some value ascribed to the pipeline here, but no small part of it, in my mind, is the IP," Skorney said by telephone. The $24.50-a-share price is more than three-times Idenix's closing price Friday. "Probably greater than 50 percent of the deal is related to these patents."
Merck is likely to seek to consolidate its suits with Idenix's, Skorney said. That could put more pressure on Gilead to settle.
"It certainly gives Merck more leverage with Gilead," he said. "It makes all the IP [challenges] go away if Gilead were to settle, instead of having to negotiate with two separate parties."
Trials around the intellectual property could take years to play out, but a settlement, Skorney said, could happen any time.
—By CNBC's Meg Tirrell